Pre-treatment systemic immune-inflammation index as a non-invasive biomarker for predicting clinical outcomes in patients with renal cell carcinoma: a meta-analysis of 20 studies

References

• Al Za’abi, M., et al., 2016b. Analyses of acute kidney injury biomarkers by ultra-high performance liquid chromatography with mass spectrometry. Journal of separation science, 39 (1), 69–82.
   PubMed Web of Science ®Google Scholar
• Al Za’abi, M., Ali, B.H., and Ali, I., 2016a. Advances in the methodologies for the analysis of acute kidney injury biomarkers. Recent patents on biomarkers, 5 (2), 81–92.
   Google Scholar
• Barua, S.K., et al., 2019. Predictors of progression-free survival and overall survival in metastatic non-clear cell renal cell carcinoma: a single-center experience. World journal of oncology, 10 (2), 101–111.
   PubMedGoogle Scholar
• Bugdayci Basal, F., et al., 2021. Can systemic immune-inflammation index create a new perspective for the IMDC scoring system in patients with metastatic renal cell carcinoma? Urologia internationalis, 105 (7–8), 666–673.
   PubMed Web of Science ®Google Scholar
• Chen, J., et al., 2021. Identification of a risk stratification model to predict overall survival and surgical benefit in clear cell renal cell carcinoma with distant metastasis. Frontiers in oncology, 11, 630842.
   PubMedGoogle Scholar
• Chrom, P., et al., 2019. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model. International journal of clinical oncology, 24 (5), 526–532.
   PubMed Web of Science ®Google Scholar
• De Giorgi, U., et al., 2019. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clinical cancer research: an official journal of the American association for cancer research, 25 (13), 3839–3846.
   PubMed Web of Science ®Google Scholar
• Demasure, S., et al., 2022. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta oncologica (Stockholm, Sweden), 61 (1), 22–29.
   PubMed Web of Science ®Google Scholar
• Dong, M., et al., 2020. Prognostic and clinicopathological significance of systemic immune-inflammation index in colorectal cancer: a meta-analysis. Therapeutic advances in medical oncology, 12, 1758835920937425.
   Web of Science ®Google Scholar
• Erdemir, F., et al., 2007. Clinical significance of platelet count in patients with renal cell carcinoma. Urologia internationalis, 79 (2), 111–116.
   PubMed Web of Science ®Google Scholar
• Fukuda, H., et al., 2018. Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Oncotarget, 9 (18), 14296–14305.
   PubMedGoogle Scholar
• Gu, L., et al., 2015. The association of platelet count with clinicopathological significance and prognosis in renal cell carcinoma: a systematic review and meta-analysis. PLoS one, 10 (5), e0125538.
   PubMed Web of Science ®Google Scholar
• Horton, B.L., et al., 2018. Intratumoral CD8(+) T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity. Cancer immunology research, 6 (1), 14–24.
   PubMed Web of Science ®Google Scholar
• Hu, X., et al., 2020. Preoperative systemic immune-inflammation index predicts prognosis of patients with non-metastatic renal cell carcinoma: a propensity score-matched analysis. Cancer cell international, 20, 222.
   PubMed Web of Science ®Google Scholar
• Huang, Y., et al., 2020. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer cell international, 20, 499.
   PubMed Web of Science ®Google Scholar
• Iinuma, K., et al., 2021. Utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index as prognostic, predictive biomarkers in patients with metastatic renal cell carcinoma treated with nivolumab and ipilimumab. Journal of clinical medicine, 10 (22), 5325.
   PubMed Web of Science ®Google Scholar
• Ji, Y., and Wang, H., 2020. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World journal of surgical oncology, 18 (1), 197.
   PubMed Web of Science ®Google Scholar
• Jia, G., et al., 2020. Platelet lysates in hepatocellular carcinoma patients after radiofrequency ablation facilitate tumor proliferation, invasion and vasculogenic mimicry. International journal of medical sciences, 17 (14), 2104–2112.
   PubMed Web of Science ®Google Scholar
• Jiang, T., et al., 2020. Prognosis and clinicopathological characteristics of renal cell carcinoma: does bilateral occurrence influence overall and cancer-specific survival? Translational cancer research, 9 (2), 432–440.
   PubMed Web of Science ®Google Scholar
• Jin, M., et al., 2021. Prognostic and clinicopathological significance of the systemic immune-inflammation index in patients with renal cell carcinoma: a meta-analysis. Frontiers in oncology, 11, 735803.
   PubMed Web of Science ®Google Scholar
• Lai, Y., et al., 2018. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma. Cancer cell international, 18, 31.
   PubMed Web of Science ®Google Scholar
• Laukhtina, E., et al., 2022a. Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva urology and nephrology, 74 (3), 329–336.
   PubMedGoogle Scholar
• Laukhtina, E., et al., 2022b. Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. World journal of urology, 40 (3), 747–754.
   PubMed Web of Science ®Google Scholar
• Li, N., 2016. Platelets in cancer metastasis: to help the "villain" to do evil. International journal of cancer, 138 (9), 2078–2087.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2021. Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis. Annals of medicine, 53 (1), 1827–1838.
   PubMed Web of Science ®Google Scholar
• Li, P., Lv, J., and Yue, J., 2022. Relationship between platelet-to-lymphocyte ratio and systemic immune-inflammation index and prognostic outcomes in patients with advanced renal cell carcinoma treated with immunecheck point inhibitors. Chinese journal of cancer prevention and treatment, 29 (7), 523–530.
   Google Scholar
• Lo, C.K., Mertz, D., and Loeb, M., 2014. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC medical research methodology, 14, 45.
   PubMed Web of Science ®Google Scholar
• Lolli, C., et al., 2016. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget, 7 (34), 54564–54571.
   PubMedGoogle Scholar
• Meng, Y., et al., 2021. Transcriptional profiling reveals kidney neutrophil heterogeneity in both healthy people and ccRCC patients. Journal of immunology research, 2021, 5598627.
   PubMed Web of Science ®Google Scholar
• Mizutani, Y., et al., 2003. The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma. Cancer, 98 (4), 730–736.
   PubMed Web of Science ®Google Scholar
• Netti, G.S., et al., 2021. Role of complement in regulating inflammation processes in renal and prostate cancers. Cells, 10 (9), 2426.
   PubMed Web of Science ®Google Scholar
• Nishida, J., et al., 2020. Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis. Nature cell biology, 22 (4), 465–475.
   PubMed Web of Science ®Google Scholar
• Ozbek, E., et al., 2020. Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma. International urology and nephrology, 52 (8), 1455–1463.
   PubMed Web of Science ®Google Scholar
• Padala, S.A., et al., 2020. Epidemiology of renal cell carcinoma. World journal of oncology, 11 (3), 79–87.
   PubMedGoogle Scholar
• Qiu, Y., Zhang, Z., and Chen, Y., 2021. Prognostic value of pretreatment systemic immune-inflammation index in gastric cancer: a meta-analysis. Frontiers in oncology, 11, 537140.
   PubMed Web of Science ®Google Scholar
• Rebuzzi, S.E., et al., 2021. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Therapeutic advances in medical oncology, 13, 17588359211019642.
   Web of Science ®Google Scholar
• Rudzinski, J.K., et al., 2020. The role of the androgen receptor in prostate cancer-induced platelet aggregation and platelet-induced invasion. Journal of thrombosis and haemostasis: JTH, 18 (11), 2976–2986.
   PubMed Web of Science ®Google Scholar
• Shi, J., et al., 2020. Impact of inflammation and immunotherapy in renal cell carcinoma. Oncology letters, 20 (5), 272.
   PubMed Web of Science ®Google Scholar
• Shui, Y., et al., 2021. Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients. Aging, 13 (16), 20585–20597.
   PubMedGoogle Scholar
• Song, W., et al., 2015. Infiltrating neutrophils promote renal cell carcinoma (RCC) proliferation via modulating androgen receptor (AR) → c-Myc signals. Cancer letters, 368 (1), 71–78.
   PubMed Web of Science ®Google Scholar
• Song, W., et al., 2015. Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2α and estrogen receptor β signals. Oncotarget, 6 (22), 19290–19304.
   PubMedGoogle Scholar
• Stühler, V., et al., 2022. Role of the systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with first-line ipilimumab plus nivolumab. Cancers, 14 (12), 2972.
   PubMed Web of Science ®Google Scholar
• Takagi, S., et al., 2018. Platelets enhance multiple myeloma progression via IL-1β upregulation. Clinical cancer research: an official journal of the American association for cancer research, 24 (10), 2430–2439.
   PubMed Web of Science ®Google Scholar
• Teishima, J., et al., 2020. Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Canadian urological association journal = Journal de l‘Association des urologues du Canada, 14 (11), E582–e587.
   PubMed Web of Science ®Google Scholar
• Tsimafeyeu, I., et al., 2017. Five-year survival of patients with metastatic renal cell carcinoma in the russian federation: results from the RENSUR5 registry. Clinical genitourinary cancer, 15 (6), e1069–e1072.
   PubMed Web of Science ®Google Scholar
• Wang, Q., et al., 2021. Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis. European review for medical and pharmacological sciences, 25 (3), 1302–1310.
   PubMed Web of Science ®Google Scholar
• Wang, W., et al., 2015. Effect of platelet-derived growth factor-B on renal cell carcinoma growth and progression. Urologic oncology, 33 (4), 168.e17-27–168.e27.
   PubMed Web of Science ®Google Scholar
• Wang, Y., et al., 2019. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis. Annals of translational medicine, 7 (18), 433.
   PubMed Web of Science ®Google Scholar
• Wang, B., Huang, Y., and Lin, T., 2020. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: a meta-analysis. Medicine, 99 (1), e18571.
   PubMed Web of Science ®Google Scholar
• Wen, X., et al., 2021. Effect of 4,5-diazafluorene derivative on γδ T cell-mediated cytotoxicity against renal cell carcinoma. Life sciences, 269, 119066.
   PubMed Web of Science ®Google Scholar
• Wu, L.S., et al., 2019. TRAIL inhibits platelet-induced colorectal cancer cell invasion. The journal of international medical research, 47 (2), 962–972.
   PubMed Web of Science ®Google Scholar
• Xu, L., et al., 2005. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer research, 65 (13), 5711–5719.
   PubMed Web of Science ®Google Scholar
• Yang, L., et al., 2021. The prognostic value of preoperative peripheral blood inflammatory markers for renal cell carcinoma. Zhonghua wai ke za zhi, 26 (7), 587–591.
   Google Scholar
• Yılmaz, H., Yılmaz, A., and Demirağ, G., 2021. Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer. Future oncology (London, England), 17 (29), 3853–3864.
   PubMed Web of Science ®Google Scholar
• Yu, X., et al., 2018. Prognostic significance of systemic immune-inflammation index in patients with clear cell renal cell carcinoma after nephrectomy. Chinese journal of clinicians, 12 (9), 483–487.
   Google Scholar
• Yücel, K.B., et al., 2022. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Scientific reports, 12 (1), 16559.
   PubMed Web of Science ®Google Scholar
• Zapała, Ł., et al., 2022a. Complete blood count-derived inflammatory markers and survival in patients with localized renal cell cancer treated with partial or radical nephrectomy: a retrospective single-tertiary-center study. Frontiers in bioscience (scholar edition), 14 (1), 5.
   PubMedGoogle Scholar
• Zapała, Ł., et al., 2022b. The four-feature prognostic models for cancer-specific and overall survival after surgery for localized clear cell renal cancer: is there a place for inflammatory markers? Biomedicines, 10 (5), 1202.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Sun, Y., and Zhang, Q., 2020. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer cell international, 20, 224.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Xiao, G., and Wang, R., 2019. Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis. Cancer management and research, 11, 4185–4200.
   PubMed Web of Science ®Google Scholar
• Zhu, J., et al., 2017. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nature communications, 8 (1), 1404.
   PubMedGoogle Scholar